BridgeBio Pharma
BridgeBio Pharma is a biotechnology company dedicated to the development of innovative therapies for genetic diseases and cancers with clear genetic drivers. Founded in 2015 and headquartered in Palo Alto, California, the company has established a robust pipeline of 20 development programs, featuring a range of product candidates from early discovery to late-stage clinical trials. Notable projects include BBP-265, an oral small molecule for the treatment of transthyretin amyloidosis, and infigratinib, a selective tyrosine kinase inhibitor aimed at addressing FGFR-driven cancers and achondroplasia. Additionally, the company is developing BBP-631, a gene transfer product for congenital adrenal hyperplasia, and BBP-454, a program targeting KRAS-driven cancers. BridgeBio collaborates with various academic institutions and research organizations to enhance its R&D efforts and accelerate the development of transformative medicines for patients with high unmet medical needs.
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.
QED Therapeutics, a biotechnology company based in San Francisco, specializes in developing precision medicines for disorders associated with Fibroblast growth factors and their receptors (FGFR). Founded in 2017, the company operates as a subsidiary of BridgeBio Pharma. Its primary focus is on infigratinib, a leading FGFR kinase inhibitor that has demonstrated significant clinical efficacy in patients with chemotherapy-refractory cholangiocarcinoma featuring FGFR2 fusions. Additionally, QED Therapeutics is exploring the use of infigratinib in preclinical studies for the treatment of achondroplasia and aims to expand its development efforts to include various FGFR-driven tumor types and rare diseases.
PellePharm, Inc. specializes in the research and development of therapeutics for skin cancer, particularly focusing on basal cell carcinoma (BCC) and basal cell nevus syndrome. Established in 2012 and located in Menlo Park, California, the company is advancing patidegib, a pioneering topical gel formulation that acts as a hedgehog pathway inhibitor. This treatment aims to alleviate the tumor burden in patients, especially those affected by Gorlin Syndrome, a rare genetic skin condition. PellePharm's objective is to enhance patient quality of life by potentially minimizing the need for invasive surgeries and reducing the associated scarring. Patidegib is currently undergoing phase 2 clinical trials to assess its efficacy in treating sporadic BCCs.
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.
MyoKardia, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases, particularly heritable cardiomyopathies and genetically-driven heart failure. Founded in 2012 and headquartered in Brisbane, California, the company focuses on addressing biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, a small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company's preclinical pipeline includes programs targeting hypercontractility and impaired relaxation in HCM, as well as treatments for diastolic dysfunction. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.